- May 2016
Mark Lemmon on the underlying biochemistry of cancer.
- April 2016
Roger Stupp on using alternating electric fields as treatment.
- March 2016
Charlotte Vrinten on public perception of deaths from cancer.
- February 2016
Guillermo Garcia-Manero on myelodysplastic syndromes (MDS).
- December 2015/January 2016
Nazneen Rahman on germline genetic screening in ovarian cancer.
- November 2015
Caroline Robert on new developments in immunotherapy.
- October 2015
Milena Sant on the latest results from the EUROCARE study.
- September 2015
The science behind the IARC code that could reduce cancer in Europe.
- July/August 2015
Thomas Helleday on an exciting new class of drug, MTH1 inhibitors.
- June 2015
Lesley Seymour and Jan Bogaerts on the future of RECIST.
- May 2015
Paul Workman on strategies for overcoming resistance to new drugs.
- April 2015
Highlights from the TAT Congress in Paris.
- March 2015
Christopher Wild on the exposome, a measure of environmental exposure.
EJC News Focus – February 2016
Unravelling the mysteries of MDS
All cancers have some epigenetic component, but myelodysplastic syndromes (MDS) are the only diseases in which hypomethylating agents have had significant clinical activity. Colon cancer, for example has as much methylation as MDS but is resistant to these agents. Why that should be remains a mystery.
At the European Cancer Congress in Vienna (September 2015), Guillermo Garcia-Manero (MD Anderson Cancer Center, Houston, Texas) presented research into this and other difficult questions in MDS. In this EJC News Focus, he tells Helen Saul that the eventual answers could have implications in a wide range of cancers.